Table of Contents

company-logo

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

TransCode Therapeutics Dividend Announcement

• TransCode Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on TransCode Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

TransCode Therapeutics Dividend History

TransCode Therapeutics Dividend Yield

TransCode Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing TransCode Therapeutics stock? Use our calculator to estimate your expected dividend yield:

TransCode Therapeutics Financial Ratios

P/E ratio-7.41
PEG ratio-0.07
P/B ratio66.93
ROE-649.01%
Payout ratio0.00%
Current ratio1.58
Quick ratio1.58
Cash Ratio0.82

TransCode Therapeutics Dividend FAQ

Does TransCode Therapeutics stock pay dividends?
TransCode Therapeutics does not currently pay dividends to its shareholders.
Has TransCode Therapeutics ever paid a dividend?
No, TransCode Therapeutics has no a history of paying dividends to its shareholders. TransCode Therapeutics is not known for its dividend payments.
Why doesn't TransCode Therapeutics pay dividends?
There are several potential reasons why TransCode Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will TransCode Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While TransCode Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is TransCode Therapeutics a dividend aristocrat?
TransCode Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is TransCode Therapeutics a dividend king?
TransCode Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is TransCode Therapeutics a dividend stock?
No, TransCode Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy TransCode Therapeutics stocks?
To buy TransCode Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy TransCode Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.